Priorities for improvement in health in patients with rheumatoid arthritis (RA) who are starting disease-modifying antirheumatic drugs (DMARDs), including biological agents

被引：0
|
作者：
Heiberg, T
Vinders, M
Olsen, CL
Magnussen, AS
Enersen, TB
Fekete, S
Kvien, TK
机构：
[1] Ullevaal Univ Hosp, Dept Adm, Oslo, Norway
[2] Lillehammer Hosp Rheumat Dis, Dept Rheumatol, Lillehammer, Norway
[3] Diakonhjemmet Hosp, Dept Rheumatol, Oslo, Norway
[4] St Olav Hosp, Dept Rheumatol, Trondheim, Norway
[5] Buskerud Cent Hosp, Dept Rheumatol, Drammen, Norway
[6] Univ Hosp No Norway, Dept Rheumatol, Tromso, Norway
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2004年 / 63卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：558 / 558
页数：1
相关论文
共 50 条
  • [1] THE HEALTH AND ECONOMIC CONSEQUENCES OF DELAY IN STARTING DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARDS) IN RHEUMATOID ARTHRITIS
    Van Doornum, S.
    Roberts, L.
    Reed, M. D.
    Liew, D.
    [J]. VALUE IN HEALTH, 2012, 15 (07) : A448 - A448
  • [2] THE HEALTH AND ECONOMIC CONSEQUENCES OF DELAY IN STARTING DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARDS) IN RHEUMATOID ARTHRITIS
    Van Doornum, S.
    Franklyn, K.
    Tacey, M.
    Roberts, C.
    Liew, D.
    [J]. INTERNAL MEDICINE JOURNAL, 2013, 43 : 2 - 2
  • [3] EFFICIENCY OF NON-BIOLOGICAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARDS) IN RHEUMATOID ARTHRITIS (RA) PATIENTS WITH COMORBIDITY
    Mykytenko, G.
    Iaremenko, O.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 212 - 213
  • [4] The effect of disease-modifying antirheumatic drugs (DMARDs) on bone homeostasis in rheumatoid arthritis (RA) patients
    Khoshroo, Ahmadreza
    Ramezani, Keyvan
    Moghimi, Niusha
    Bonakdar, Moein
    Ramezani, Nazanin
    [J]. INFLAMMOPHARMACOLOGY, 2023, 31 (02) : 689 - 697
  • [5] The effect of disease-modifying antirheumatic drugs (DMARDs) on bone homeostasis in rheumatoid arthritis (RA) patients
    Ahmadreza Khoshroo
    Keyvan Ramezani
    Niusha Moghimi
    Moein Bonakdar
    Nazanin Ramezani
    [J]. Inflammopharmacology, 2023, 31 : 689 - 697
  • [6] Utilization of disease modifying antirheumatic drugs (DMARDs) among patients with rheumatoid arthritis (RA).
    MacLean, CH
    Park, GS
    Traina, SB
    Liu, HH
    Hahn, BH
    Paulus, HE
    Kahn, KI
    [J]. ARTHRITIS AND RHEUMATISM, 2001, 44 (09): : S143 - S143
  • [7] Assessment of adherence to and persistence on disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis
    Grijalva, Carlos G.
    Chung, Cecilia P.
    Arbogast, Patrick G.
    Stein, Charles M.
    Mitchel, Edward F., Jr.
    Griffin, Marie R.
    [J]. MEDICAL CARE, 2007, 45 (10) : S66 - S76
  • [8] Is there still a role for traditional disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis?
    Cannella, AC
    O'Dell, JR
    [J]. CURRENT OPINION IN RHEUMATOLOGY, 2003, 15 (03) : 185 - 192
  • [9] Predictors of Stopping and Starting Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis
    Solomon, Daniel H.
    Tonner, Chris
    Lu, Bing
    Kim, Seoyoung C.
    Ayanian, John Z.
    Brookhart, M. Alan
    Katz, Jeffrey N.
    Yelin, Ed
    [J]. ARTHRITIS CARE & RESEARCH, 2014, 66 (08) : 1152 - 1158
  • [10] Safety of biological disease-modifying antirheumatic drugs in rheumatoid arthritis
    Martinez-Mugica, Cristina
    Salgueiro, Esther
    [J]. FARMACIA HOSPITALARIA, 2022, 46 (01) : 15 - 20
12345